Gerold Bepler, Ralph G. Zinner, James Moon, Royce Calhoun, Kemp Kernstine, Charles C. Williams, Philip C. Mack, Vasco Oliveira, Zhong Zheng, Philip J. Stella, Mary W. Redman and David R. Gandara A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701) Cancer 120
Version of Record online: 18 APR 2014 | DOI: 10.1002/cncr.28714
Excision repair cross-complementing group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) are promising predictive markers for the efficacy of platinum agents and gemcitabine. The current phase 2 trial was designed to assess the feasibility and preliminary efficacy of using molecular testing of surgically resected tumor specimens for therapeutic decision-making in a cooperative group environment.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field